Inhibrx Ár/értékesítés
Mi az Inhibrx Ár/értékesítés?
A Ár/értékesítés az Inhibrx, Inc. - 691.46
Mi a Ár/értékesítés meghatározása?
Az ár / árbevétel arány a vállalat részvényeinek árbevételéhez képest.
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
Ár/értékesítés a Health Care szektor a NASDAQ-on cégekben a Inhibrx -hoz képest
Mit csinál Inhibrx?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
ár/értékesítés -hoz hasonló cégek Inhibrx
- Insilco nak Ár/értékesítés 672.80 van
- Uranium Participation nak Ár/értékesítés 673.57 van
- Kadestone Capital nak Ár/értékesítés 679.35 van
- Nuveen Municipal Credit Opportunities Fund nak Ár/értékesítés 682.87 van
- Great Boulder Resources nak Ár/értékesítés 687.08 van
- Global Atomic nak Ár/értékesítés 690.39 van
- Inhibrx nak Ár/értékesítés 691.46 van
- Thin Film Electronics ASA nak Ár/értékesítés 694.91 van
- BioPharmX nak Ár/értékesítés 695.03 van
- Petro Matad nak Ár/értékesítés 698.32 van
- Chesser Resources nak Ár/értékesítés 703.97 van
- Prospect Park Capital nak Ár/értékesítés 709.23 van
- Shonghoya Intl Inc nak Ár/értékesítés 712.65 van